PL2877460T3 - Krystaliczny kompleks 1-cyjano-2-(4-cyklopropylo-benzylo)-4-(ß-D-glukopiranoz-1-ylo)-benzenu, sposoby jego wytwarzania i jego zastosowanie do wytwarzania leków - Google Patents

Krystaliczny kompleks 1-cyjano-2-(4-cyklopropylo-benzylo)-4-(ß-D-glukopiranoz-1-ylo)-benzenu, sposoby jego wytwarzania i jego zastosowanie do wytwarzania leków

Info

Publication number
PL2877460T3
PL2877460T3 PL13740309T PL13740309T PL2877460T3 PL 2877460 T3 PL2877460 T3 PL 2877460T3 PL 13740309 T PL13740309 T PL 13740309T PL 13740309 T PL13740309 T PL 13740309T PL 2877460 T3 PL2877460 T3 PL 2877460T3
Authority
PL
Poland
Prior art keywords
glucopyranos
cyclopropyl
cyano
benzyl
benzene
Prior art date
Application number
PL13740309T
Other languages
English (en)
Polish (pl)
Inventor
Matthias Eckhardt
Tanja Butz
Frank Himmelsbach
Hans-Juergen Martin
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of PL2877460T3 publication Critical patent/PL2877460T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04Carbocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13740309T 2012-07-26 2013-07-25 Krystaliczny kompleks 1-cyjano-2-(4-cyklopropylo-benzylo)-4-(ß-D-glukopiranoz-1-ylo)-benzenu, sposoby jego wytwarzania i jego zastosowanie do wytwarzania leków PL2877460T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12177944 2012-07-26
EP13740309.3A EP2877460B1 (en) 2012-07-26 2013-07-25 CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß-D-GLUCOPYRANOS-1-YL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
PCT/EP2013/065736 WO2014016381A1 (en) 2012-07-26 2013-07-25 CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß- D-GLUCOPYRANOS-1-YL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS

Publications (1)

Publication Number Publication Date
PL2877460T3 true PL2877460T3 (pl) 2019-04-30

Family

ID=48874313

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13740309T PL2877460T3 (pl) 2012-07-26 2013-07-25 Krystaliczny kompleks 1-cyjano-2-(4-cyklopropylo-benzylo)-4-(ß-D-glukopiranoz-1-ylo)-benzenu, sposoby jego wytwarzania i jego zastosowanie do wytwarzania leków
PL18155079.9T PL3351539T3 (pl) 2012-07-26 2013-07-25 Krystaliczny kompleks monohydratowy 1-cyjano-2-(4-cyklopropylo-benzylo)-4-(beta-d-glukopiranoz-1-ylo)-benzenu i proliny w wodzie krystalicznej (1:1:1), sposoby jego wytwarzania i jego zastosowanie jako inhibitor sglt

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18155079.9T PL3351539T3 (pl) 2012-07-26 2013-07-25 Krystaliczny kompleks monohydratowy 1-cyjano-2-(4-cyklopropylo-benzylo)-4-(beta-d-glukopiranoz-1-ylo)-benzenu i proliny w wodzie krystalicznej (1:1:1), sposoby jego wytwarzania i jego zastosowanie jako inhibitor sglt

Country Status (23)

Country Link
US (1) US9145434B2 (cg-RX-API-DMAC7.html)
EP (3) EP4166548A1 (cg-RX-API-DMAC7.html)
JP (2) JP6538556B2 (cg-RX-API-DMAC7.html)
CN (2) CN104470908A (cg-RX-API-DMAC7.html)
AR (1) AR091908A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013294947B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015001327B1 (cg-RX-API-DMAC7.html)
CA (1) CA2878698C (cg-RX-API-DMAC7.html)
DK (2) DK2877460T3 (cg-RX-API-DMAC7.html)
EA (2) EA025438B1 (cg-RX-API-DMAC7.html)
ES (2) ES2694675T3 (cg-RX-API-DMAC7.html)
FI (1) FI3351539T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20230081T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061450T2 (cg-RX-API-DMAC7.html)
LT (1) LT3351539T (cg-RX-API-DMAC7.html)
MX (1) MX357906B (cg-RX-API-DMAC7.html)
PL (2) PL2877460T3 (cg-RX-API-DMAC7.html)
PT (2) PT2877460T (cg-RX-API-DMAC7.html)
RS (1) RS63881B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201500574QA (cg-RX-API-DMAC7.html)
SI (2) SI2877460T1 (cg-RX-API-DMAC7.html)
TW (1) TW201418275A (cg-RX-API-DMAC7.html)
WO (1) WO2014016381A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
FI2981269T3 (fi) 2013-04-04 2023-09-27 Boehringer Ingelheim Vetmedica Gmbh Aineenvaihduntahäiriöiden hoito hevoseläimillä
HUE065346T2 (hu) 2013-12-17 2024-05-28 Boehringer Ingelheim Vetmedica Gmbh Macskafélék anyagcserezavarainak kezelése
RS64355B1 (sr) 2014-01-23 2023-08-31 Boehringer Ingelheim Vetmedica Gmbh Sglt2 inhibitori za lečenje metaboličkih poremećaja kod životinja iz roda kanin
EP3125882B1 (en) 2014-04-01 2020-05-13 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in equine animals
CN103965020B (zh) * 2014-05-06 2015-09-09 启东东岳药业有限公司 制备5-碘-2-溴苄醇的方法
PL3197429T3 (pl) 2014-09-25 2024-09-30 Boehringer Ingelheim Vetmedica Gmbh Leczenie skojarzone inhibitorami sglt2 i agonistami dopaminy do profilaktyki zaburzeń metabolicznych u zwierząt koniowatych
ES2836099T3 (es) * 2014-09-30 2021-06-24 Jiangsu Hengrui Medicine Co Cristal de un complejo de L-prolina/inhibidor del cotransportador de sodio-glucosa tipo 2
CZ2015110A3 (cs) * 2015-02-18 2016-08-31 Zentiva, K.S. Pevné formy empagliflozinu
HUE069575T2 (hu) 2015-08-27 2025-03-28 Boehringer Ingelheim Vetmedica Gmbh Folyékony gyógyászati készítmények, amelyek SGLT-2-inhibitorokat tartalmaznak
WO2017203457A1 (en) * 2016-05-26 2017-11-30 Dr. Reddy's Laboratories Limited Solid state forms of empagliflozin
KR102226465B1 (ko) 2016-05-28 2021-03-11 하이난 수안주 파마 코포레이션 리미티드 나트륨-글루코스 공수송체 2에 대한 억제제의 결정형
EA202091466A1 (ru) 2017-12-19 2020-10-23 Бёрингер Ингельхайм Ветмедика Гмбх Синтез сокристалла 1:1:1 1-циано-2-(4-циклопропилбензил)-4-(-d-глюкопираноз-1-ил)бензола, l-пролина и воды
JP7441946B2 (ja) 2019-11-28 2024-03-01 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 非ヒト動物の乾乳におけるsglt-2阻害剤の使用
CN118615450A (zh) 2020-02-17 2024-09-10 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途
US20240307426A1 (en) 2021-07-28 2024-09-19 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
JP2024527434A (ja) 2021-07-28 2024-07-24 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ネコ科動物を除く非ヒト哺乳動物、特にイヌ科動物における心臓疾患の予防及び/又は治療のためのsglt-2阻害剤の使用
TW202412756A (zh) 2022-05-25 2024-04-01 德商百靈佳殷格翰維美迪加股份有限公司 包含sglt-2抑制劑之水性醫藥組合物
CN120857933A (zh) 2023-03-06 2025-10-28 勃林格殷格翰动物保健有限公司 用于递送特别包含一或多种sglt-2抑制剂的液体药物组合物的系统
CN121039113A (zh) 2023-04-24 2025-11-28 勃林格殷格翰动物保健有限公司 维格列净与所选共晶形成剂的结晶复合物、其制备方法及其在制备药物中的用途
WO2024240633A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
WO2024240632A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60209343T2 (de) 2001-04-11 2006-10-26 Bristol-Myers Squibb Co. Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
CN101260130A (zh) * 2003-01-03 2008-09-10 布里斯托尔-迈尔斯斯奎布公司 制备c-芳基葡糖苷sglt2抑制剂的方法
ME01422B (me) * 2004-03-16 2013-12-20 Boehringer Ingelheim Int Derivati benzola supstituisani glukopiranozilom, ljekovi koji sadrže navedena jedinjenja, njihova primjena i njihov postupak proizvodnje
TW200745075A (en) * 2005-09-08 2007-12-16 Boehringer Ingelheim Int Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
US7745414B2 (en) 2006-02-15 2010-06-29 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
AR065809A1 (es) 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
EP2147008A2 (en) * 2007-05-18 2010-01-27 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for preparing same
CN101468976B (zh) * 2007-12-27 2013-11-20 百时美施贵宝公司 Sglt2抑制剂的晶体结构及其制备方法
RS55555B1 (sr) * 2008-08-22 2017-05-31 Theracos Sub Llc Postupci za pripremu inhibitora sglt2
AP2728A (en) 2008-08-28 2013-08-31 Pfizer Dioxa-bicyclo[3.2.1.] octane-2,3,4-triol derivatives
US20100167988A1 (en) 2008-10-22 2010-07-01 Auspex Pharmaceuticals, Inc. Ethoxyphenylmethyl inhibitors of sglt2
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
FI2981269T3 (fi) 2013-04-04 2023-09-27 Boehringer Ingelheim Vetmedica Gmbh Aineenvaihduntahäiriöiden hoito hevoseläimillä

Also Published As

Publication number Publication date
DK3351539T3 (da) 2023-01-30
AR091908A1 (es) 2015-03-11
EA201500038A1 (ru) 2015-07-30
TW201418275A (zh) 2014-05-16
DK2877460T3 (en) 2019-01-07
EP2877460B1 (en) 2018-09-12
PT2877460T (pt) 2018-12-19
EA201600506A1 (ru) 2017-03-31
US9145434B2 (en) 2015-09-29
EA025438B1 (ru) 2016-12-30
EP4166548A1 (en) 2023-04-19
HRP20230081T1 (hr) 2023-03-17
BR112015001327A2 (pt) 2017-07-04
SI2877460T1 (sl) 2018-12-31
JP2015522644A (ja) 2015-08-06
PT3351539T (pt) 2023-01-17
HUE061450T2 (hu) 2023-07-28
EP3351539A1 (en) 2018-07-25
HRP20181972T1 (hr) 2019-01-25
MX2015000962A (es) 2015-04-16
LT3351539T (lt) 2023-02-10
SI3351539T1 (sl) 2023-03-31
JP2018135384A (ja) 2018-08-30
AU2013294947A1 (en) 2015-01-22
CA2878698C (en) 2021-03-23
ES2937665T3 (es) 2023-03-30
FI3351539T3 (fi) 2023-02-19
US20140031540A1 (en) 2014-01-30
BR112015001327B1 (pt) 2022-08-16
RS63881B1 (sr) 2023-02-28
EP3351539B1 (en) 2022-11-09
JP6538556B2 (ja) 2019-07-03
ES2694675T3 (es) 2018-12-26
AU2013294947B2 (en) 2017-03-30
MX357906B (es) 2018-07-30
CN108774200A (zh) 2018-11-09
PL3351539T3 (pl) 2023-03-06
CN104470908A (zh) 2015-03-25
EP2877460A1 (en) 2015-06-03
CA2878698A1 (en) 2014-01-30
WO2014016381A1 (en) 2014-01-30
SG11201500574QA (en) 2015-02-27

Similar Documents

Publication Publication Date Title
SG11201500574QA (en) CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß- D-GLUCOPYRANOS-1-YL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
IL231386A0 (en) Pyrazoloquinolinone derivatives, their preparation and medical use
IL231382A (en) History of benzonitrile, their preparation and medications containing them
HRP20181704T1 (hr) Kristalni oblik kidamida, metoda pripreme i uporabe istog
PT2687539T (pt) Variante de anexina v sua preparação e utilização
EP2933250A4 (en) PHENYL-C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USE THEREOF
IL233602A0 (en) History of benzamide, their preparation and pharmaceutical preparations containing them
EP2924042A4 (en) BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL242437B (en) Compound 9, 5-dimethyl-9-hydroxy-decan-4-al, its use and its preparation process
IL233238A (en) Sulphonylaminopyrrolidinone derivatives, their preparation and therapeutic use
IL239146A0 (en) Aminocyclobutane derivatives, methods for their preparation and their use as drugs
PT2870145T (pt) Derivados de indeno, sua preparação e utilização como medicamentos
EP2929894A4 (en) VACCINE ADJUVANS, PREPARATION AND VACCINES THEREOF
ZA201501597B (en) Macrolide derivatives,preparation thereof and therapeutic use thereof
ZA201407214B (en) Therapeutic preparation and process for preparing said therapeutic preparation
SG11201405376TA (en) CRYSTALLINE FORMS OF 5α-ANDROSTANE-3β, 5, 6β-TRIOL AND PREPARATION METHODS THEREOF
PL398021A1 (pl) Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
PL398018A1 (pl) Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
GB201112642D0 (en) Surgical hair preparation substance
PL396025A1 (pl) Nowy 7-siarczan 8-prenylonaringeniny i sposób jego wytwarzania
HK1195303A (en) Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
AP2015008270A0 (en) Preparation for the treatment of tuberculosis